Transine Therapeutics

Transine Therapeutics is developing a novel class of therapeutic RNAs that have the property to drive up protein expression with an unprecedented level of control and specificity: The SINEUP® platform. Our SINEUPs are designed to precisely bind to a target mRNA and boost expression of almost any chosen protein by enhancing its rate of translation. The unique characteristics of SINEUPs allow us to safely and effectively address diseases which have been beyond the reach of small molecules, conventional biologics or gene therapies.

We are building a culture of collaboration, ambition and innovation - all with one purpose: To deliver on our passion to develop life-changing therapeutics for serious, underserved diseases. Transine holds broad granted patent protection and we exploit the vast therapeutic capability of the SINEUP technology starting with lead indications in ophthalmology and CNS disease. We are headquartered in the heart of the biotech hub of Cambridge, UK.